Ubigene Biosciences
This installment of Supplier Spotlight® highlights Ubigene, a CRO that focuses on gene-editing in cells (KO/KI/PM), CRISPR library screening and stable cell establishment, assisting in accelerating drug discovery and validation. Their services are available on the Scientist.com marketplace.
1. What is your company’s mission?
Make genome editing easier is Ubigene’s goal. We continuously increase our R&D investment to promote technological innovation and breakthroughs, while optimizing our production system to ensure large-scale and high-throughput production capacity. In addition, we have developed a series of gene-editing products that not only enhance our market competitiveness but also bring value and convenience to our customers.
2. What products and services do you offer?
- Core Technical Services: Gene-editing (knockout/knock-in/point mutation) cell line, CRISPR library screening and stable cell line.
- Off-the-Shelf Cell Products: Red Cotton™ Cell Bank gathers over 5000 cell products, including KO cells, Luciferase cells and wild-type cells.
- Gene-editing Series Products: EZ-editor™ Series Products cover the entire process of cell gene editing, including reagent kits, lentiviruses, etc.
3. What problems do you solve?
Our CRISPR iScreen™ technique can achieve high-throughput target discovery, and our CRISPR-U™ technique can perform target validation in high efficiency. Lastly, our Red Cotton™ Commercialized Cell Bank can accelerate drug screening, and together, these solutions can help scientists accelerate the drug development process.
4. What are the most innovative tools and technologies that you offer?
- Red Cotton™ CRISPR Gene Editing System is a high-throughput, large-scale solution-design and sequencing-result analysis system. Its unique algorithm ensures efficient editing solutions. It visualizes the strategy risk from the dimensions of gene lethality, expression level and copy number.
- The CRISPR-U™ Technique, improved from CRISPR/Cas9 technology, greatly increased the gene-editing efficiency by 10-20 times. The annual production capacity of KO cells now exceeds 4,000.
- The CRISPR-iScreen™ Technique can ensure the quality of CRISPR library plasmid amplification reaches coverage>99% and uniformity<10. The Cell Pool library has a coverage rate of up to 99%, achieving high-throughput and large-scale production of library products
5. What are your competitive advantages?
- Ubigene has over 4,500 types of KO cells in stock, covering 12 major research fields, with delivery times as fast as 1 week.
- By 2024, we have accumulated 15 years of rich experience in gene editing, with over 6,000 successful project cases and successfully achieved editing on 300+ cell lines.
6. Who are your clients?
Ubigene has provided high-quality gene editing services and products for thousands of life science laboratories, pharmaceutical and CROs from more than 40 countries worldwide, including 8 out of top 10 global pharmaceutical companies.
7. What new products and services are you developing in 2024/2025?
Ubigene continuously develops and innovates and has optimized multiple core technologies in 2024:
- CRISPR Library Screen: The CRISPR-iScreen™ Technique ensures the quality of library plasmid amplification, helping researchers achieve large-scale and standardized production of library products.
- Stable Cell Line: The EZ-OE™ Technique utilizes an exclusive transposition system for site-specific single-copy integration without the need for viruses, and can easily achieve gene stable expression.
- CRISPR KI/PM: The EZ-HRex™ Technique can achieve an HDR efficiency of up to 84% for gene mutations and fragment KI in cells, enabling rapid delivery in 6 weeks.
8. Where are your laboratories and offices located?
Ubigene is located in Guangzhou City, China, and has 3000㎡ of office areas and laboratories, involving genome editing technology and cell biology platforms and a complete series of gene-editing products for different phases of experiment. Ubigene also has offices in the US, Europe and the Asia Pacific region. Our address and contact information can be found at https://www.ubigene.us/about/contact/.